1. Главная
  2. Ресурсы
  3. Библиотечный поиск
CD4 cell countresponse tofirst-linecombination ART inHIV-2+ patientscompared with HIV-1+patients: amultinational,multicohort Europeanstudy Linda WittkopJulie ArsandauxAna Treviño2017 год

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study
статья из журнала

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL).ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models.We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36-52) and 37 years (IQR 31-44), respectively. Median observed pretreatment CD4 cell counts/mm3 were 203 (95% CI 100-290) in HIV-2+ patients and 223 (95% CI 100-353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12 months were +105 (95% CI 77-134) in HIV-2+ patients and +202 (95% CI 199-205) in HIV-1+ patients, an observed difference of 97 cells/mm3 in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm3/year lower (95% CI 5-44; P = 0.0127) in HIV-2+ patients compared with HIV-1+ patients.A poorer CD4 cell increase during first-line cART was observed in HIV-2+ patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2.
Год издания: 2017
Авторы: Linda Wittkop, Julie Arsandaux, Ana Treviño, Maarten Schim van der Loeff, Jane Anderson, Ard van Sighem, Jürg Böni, Françoise Brun‐Vézinet, Vincent Soriano, Faroudy Boufassa, Norbert H. Brockmeyer, Alexandra Calmy, François Dabis, Inmaculada Jarrín, Maria Dorrucci, Vítor Duque, Gerd Fätkenheuer, Robert Zangerle, Elena Ferrer, Kholoud Porter, Ali Judd, Nikolaos V. Sipsas, Olivier Lambotte, Leah Shepherd, Catherine Leport, Charles Morrison, Cristina Mussini, Niels Obel, Jean Ruelle, C Schwarze-Zander, Anders Sönnerborg, Ramón Teira, Carlo Torti, Emília Valadas, Céline Colin, Nina Friis‐Møller, Dominique Costagliola, Rodolphe Thiébaut, Geneviéve Chêne, Sophie Matheron
Издательство: Oxford University Press
Источник: Journal of Antimicrobial Chemotherapy
Ключевые слова: HIV Research and Treatment, HIV/AIDS Research and Interventions, HIV/AIDS drug development and treatment
Другие ссылки: Journal of Antimicrobial Chemotherapy (PDF)
Journal of Antimicrobial Chemotherapy (HTML)
HAL (Le Centre pour la Communication Scientifique Directe) (HTML)
IRIS UNIMORE (University of Modena and Reggio Emilia) (PDF)
IRIS UNIMORE (University of Modena and Reggio Emilia) (HTML)
Zurich Open Repository and Archive (University of Zurich) (HTML)
UCL Discovery (University College London) (PDF)
UCL Discovery (University College London) (HTML)
UCL Discovery (University College London) (HTML)
UCL Discovery (University College London) (HTML)
UCL Discovery (University College London) (HTML)
PubMed (HTML)